Cerebrospinal fluid tau and amyloid β42 protein in patients with myotonic dystrophy type 1
Article first published online: 14 JUL 2008
© 2008 The Author(s). Journal compilation © 2008 EFNS
European Journal of Neurology
Volume 15, Issue 9, pages 947–952, September 2008
How to Cite
Winblad, S., Månsson, J. E., Blennow, K., Jensen, C., Samuelsson, L. and Lindberg, C. (2008), Cerebrospinal fluid tau and amyloid β42 protein in patients with myotonic dystrophy type 1. European Journal of Neurology, 15: 947–952. doi: 10.1111/j.1468-1331.2008.02217.x
- Issue published online: 11 AUG 2008
- Article first published online: 14 JUL 2008
- Received 9 February 2008 Accepted 27 May 2008
- cerebrospinal fluid;
- myotonic dystrophy type 1;
Background: Myotonic dystrophy type 1 (DM1) is associated with brain morphology changes including neurofibrillary degeneration.
Methods: We have examined cerebrospinal fluid (CSF) markers indicative of neuronal degeneration and amyloidogenesis; total tau (T-tau), phosphorylated tau (P-tau) and β amyloid1–42 (Aβ42), in 32 patients with DM1.
Results and conclusions: Associations between CSF markers and CTG repeat expansion size, brain MRI findings, and neuropsychological test results were analysed. As compared with matched controls Aβ42 was significantly decreased (P = 0.001), whilst levels of T-tau were increased (P < 0.001). No difference was found between measures considering P-tau levels. At present the clinical implications of these findings is unclear, because of an overlap between CSF values of DM1 patients and healthy controls, but also regarding modest associations between CSF markers and other measures. However notably, the Tau pathology, as seen in DM1, differs from Alzheimers disease, considering the lack of increased levels of P-tau.